Clinical Study
Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease
Table 1
Baseline characteristics of patients in the 3- and 12-month DAPT groups.
| | | 3-month DAPT
| 12-month DAPT
| value |
| | Male gender, n (%) | 43 (64.8) | 31 (51.8) | 0.05 | | Age, yrs | 70.3 ± 9.8 | 70.8 ± 9.2 | NS | | Stable angina, n (%) | 52 (78.2) | 48 (78.7) | NS | | Acute coronary syndrome, n (%) | 15 (21.8) | 14 (23.0) | NS | | Prior myocardial infarction, n (%) | 10 (14.8) | 8 (13.1) | NS | | Prior PCI, n (%) | 18 (27.3) | 18 (29.5) | NS | | Prior CABG, n (%) | 3 (4.5) | 1 (1.6) | NS | | Heart failure, n (%) | 7 (10.2) | 8 (13.1) | NS | | Diabetes mellitus, n (%) | 33 (49.2) | 30 (49.2) | NS | | Hypertension, n (%) | 59 (87.5) | 49 (80.3) | NS | | Dyslipidemia, n (%) | 50 (74.6) | 46 (75.4) | NS | | Current smoker, n (%) | 34 (50.8) | 21 (34.3) | 0.02 | | Cr: >2.0 mg/dL, n (%) | 5 (6.8) | 7 (11.5) | NS |
|
|
DAPT: dual antiplatelet therapy; PCI: percutaneous coronary intervention; Cr: creatinine; NS: not significant.
|
